Glaucocalyxin A Attenuates IL-1β-Induced Inflammatory Response and Cartilage Degradation in Osteoarthritis Chondrocytes via Inhibiting the Activation of NF-κB Signaling Pathway

Weidong Zhu,1 Yi Zhang,2 Yueshan Li,3 and Hao Wu1

1The Department of Orthopedics, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710004 Shaanxi Province, China
2The Department of Ophthalmology, The Second Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710004 Shaanxi Province, China
3The Department of Stomatology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, 710061 Shaanxi Province, China

Correspondence should be addressed to Hao Wu; dihaoji62588049@126.com

Received 20 December 2021; Revised 18 January 2022; Accepted 26 January 2022; Published 26 February 2022

Academic Editor: Yaoyao Bian

Copyright © 2022 Weidong Zhu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Glaucocalyxin A (GLA) is a bioactive natural compound with anti-inflammatory activity. Herein, the role of GLA in osteoarthritis (OA) was evaluated. Our results demonstrated that the IL-1β-induced inducible nitric oxide synthase (iNOS) and cyclo-oxygenase-2 (COX-2) expression, two enzymes resulting in the release of nitric oxide (NO) and PGE2, were also prevented by GLA in chondrocytes. Moreover, GLA suppressed inflammatory cytokines production in chondrocytes. In addition, the elevated expressions of MMPs and ADAMTSs and the degradation of aggrecan and collagen II were reversed by GLA in chondrocytes. Furthermore, GLA decreased p-p65 level and suppressed the nuclear p65 accumulation in the nucleus of chondrocytes. Collectively, we concluded that GLA attenuated inflammatory response in chondrocytes via NF-κB pathway. These findings suggested that GLA might become an effective agent for OA treatment.

1. Introduction

Osteoarthritis (OA) is a frequent inflammation-related disease affecting individuals over 60 years of age [1]. OA is clinically presented with crepitus, joint pain, stiffness, tenderness, and limited movement [2]. Thus, OA patients commonly suffer with functional decline as well as loss of quality, accompanied by heavy health care and society costs. Although osteoarthritis management consists of joint replacement for end-stage disease, the prevention and the treatment of early OA are still limited [1].

The identification of risk factors and understanding of the pathogenesis are central for selecting targets for OA therapy. It is evident for the role of chronic inflammation in the development of OA [3, 4]. Inflammation contributes to the evolution of joint tissue degradation and remodeling as well as joint pain [5]. A plethora of inflammatory mediators and signaling pathways are involved in the OA pathogenesis, which become potential biomarkers or therapeutic targets [6]. It is increasingly evident that interleukin-1β- (IL-1β-) mediated signaling pathways play central roles in OA pathology [7]. It is believed that components in the IL-1β signaling may be developed into novel drugs for OA.

Glaucocalyxin A (GLA), a bioactive natural compound, possesses important biological activities including anti-inflammatory activity [8–12]. Its chemical structure is shown in Figure 1(a). The administration of GLA reduces inflammation and mortality in lipopolysaccharide- (LPS-) induced septic shock mouse model through regulating NLRP3 inflammasome activation [13]. Another study has proven that the LPS-stimulated increased production of pro-inflammatory cytokines in microglia is inhibited by GLA.
Moreover, treatment with GLA reduces the inflammatory response in hydrogen peroxide- (H₂O₂-) induced smooth muscle cells [15]. Herein, we examined the potential role of GLA in OA.

Evidence has been building that the inflammatory process in chondrocytes plays crucial role in the joint injury. Thus, IL-1β-induced chondrocytes are generally applied for in vitro model of OA [7]. Herein, we examined the effect of GLA on inflammation in chondrocytes.

2. Materials and Methods

2.1. Cell Culture and Treatment. Articular cartilage samples were obtained from articular joints of OA patients undergoing total knee replacement surgery. Primary human OA chondrocytes were then harvested from these clinical samples as previously described [16]. The resulting cells were centrifuged and cultured for our following study.

The experiments were divided into five groups: control, IL-1β, IL-1β + GLA (5 μM), IL-1β + GLA (10 μM), and IL-1β + GLA (20 μM).

2.2. Cell Viability Assay. We performed cell viability assay using CCK-8 kit (Promega Corp, Madison, WI). After the treatment with GLA (0, 5, 10, 20, and 40 μM; Yuanye Biotech, Shanghai, China), the cells were treated with CCK-8 for 4 h. The OD value was measured at 450 nm.

2.3. Measurement of Nitric Oxide (NO). Primary human OA chondrocytes were incubated with different concentrations of GLA (0, 5, 10, and 20 μM) for 2 h and then stimulated with IL-1β (10 ng/ml) for 24 h. NO accumulation was measured using a commercial assay kit (Dojindo Laboratories, Kumaoto, Japan). The absorbance at 550 nm was measured and calculated for NO accumulation.

2.4. qRT-PCR. The total RNA from human OA chondrocytes was used for cDNA synthesis with cDNA Reverse Transcription Kit. The obtained cDNA was used for qRT-PCR. The primer sequences used are listed as follows: inducible nitric oxide synthase (iNOS), 5′-GAA ACT TCT CAG CCA CCT TGG-3′, and 5′-CCG TGG GGC TTG TAG TTG AC-3′; cyclooxygenase-2 (COX-2), 5′-GGT GAA AAC TGT ACT ACG CCG A-3′; and 5′-ACT CCC TTG AAG TGG GTC AG-3′; TNF-α, 5′-CAT CTT CTC AAA ATT CGA GTG ACA A-3′, and 5′-TGG GAG TAG ACA AGG TAC AAC CC-3′; IL-6, 5′-AGA AAT CCC TCC
TCG CCA AT-3′, and 5′-AAA TAG CGA ACG GCC CTC A-3′; IL-8, 5′-GCC CTC CTC CTG GTT TCA G-3′, and 5′-TGG CAC CGC AGC TCA TT-3′; matrix metalloproteinase (MMP)-3, 5′-TGA GGA CAC CAG CAT GAA CC-3′, and 5′-TGC GCT GG CAA AGC TCA TT-3′; MMP-13, 5′-GCC ATT ACC AGT CTC CGA GG-3′, and 5′-TAC GGT TGG GAA GTT CTG GC-3′; A disintegrin-like and metalloproteinase with thrombospondin type I motifs (ADAMTS)-4, 5′-CAT CCT ACG CCG GAA GAG TC-3′, and 5′-ACA CAC GGA GGT TCT GTA GG-3′; aggrecan, 5′-AAG TGC TAT GCT GGC TGG TT-3′, and 5′-CTG TGG GTG GTA GAG GT-3′; collagen II, 5′-CTC AAG TCG CTG AAC AAC CA-3′, and 5′-GTC TCC GCT CTT CCA CTC CGA GCT TG-3; and β-actin, 5′-ACT CTT CCA GCC TTC CT-3′, and 5′-TGT TGG CGT ACA GGT CTT TG-3′.

2.5. Western Blot. Control and treated chondrocytes were lysed, followed by SDS-PAGE electrophoresis as previously described [13]. The primary antibodies used were listed: anti-iNOS, anti-COX-2, anti-β-actin, and HRP-conjugated secondary antibody from Santa Cruz Biotechnology, Santa Cruz, CA; and anti-ADAMTS-4, anti-ADAMTS-5, anti-aggrecan, anti-collagen II, anti-p65, anti-p-p65, anti-p-IκBα, and anti-IκBα from Abcam. Finally, the bands were visualized with the ECL reagent.

2.6. Elisa. The culture supernatants of chondrocytes were collected, centrifugated, and frozen at -80°C until assayed. Prostaglandin E2 (PGE2), TNF-α, IL-6, IL-8, and MMP-3 and MMP-13 contents were measured by ELISA (Boster Immunoleader, Pleasanton, CA).

Figure 3: GLA inhibits the expression of iNOS and COX-2 in IL-1β-stimulated OA chondrocytes. Primary human OA chondrocytes were incubated with different concentrations of GLA (0, 5, 10, and 20 μM) for 2 h and then stimulated with IL-1β (10 ng/ml) for 24 h. (a and b) The mRNA levels of iNOS and COX-2 were evaluated using qRT-PCR. (c) The protein levels of iNOS and COX-2 were evaluated using western blot. *p < 0.05 versus the control group; #p < 0.05 versus the IL-1β group.
2.7. Immuno-fluorescence Staining. After the completion of treatment, chondrocytes were fixed, permeabilized, and blocked for 1 h. Then, cells were probed with anti-p65 antibody (Abcam) overnight, followed by an incubation with anti-rabbit Alexa Fluor 546 secondary antibodies for 2 h. Cells were then mounted with DAPI and visualized by Olympus FV1000 confocal microscope (Olympus, Tokyo, Japan).

2.8. Statistical Analysis. Experimental data are presented as mean ± S.E.M. ANOVA was performed to show the difference between groups. *p < 0.05 was considered as significant difference.

3. Results

3.1. Effect of GLA on OA Chondrocyte Viability. According to the results of Figure 1(b), GLA did not exhibit obvious cytotoxic effect on chondrocytes at the doses of 5, 10, and 20 μM. Hence, these three concentrations were used for the next experiments.

3.2. Effect of GLA on NO and PGE2 Production. A rapid increase in the NO production was observed in IL-1β-induced chondrocytes, and this response was mitigated in the GLA-treated groups (Figure 2(a)). Besides, an acute increase in PGE2 content was noted in response to induction with IL-1β, while the GLA-treated chondrocytes showed significant mitigation in PGE2 content (Figure 2(b)).

3.3. Effect of GLA on iNOS and COX-2 Expression. IL-1β could increase the mRNA levels of iNOS and COX-2, these effects were reversed by GLA (Figures 3(a) and 3(b)). Chondrocytes in the IL-1β-treated group had significant higher protein levels of iNOS and COX-2, while GLA suppressed these proteins expression (Figure 3(c)).

3.4. Effect of GLA on Inflammatory Cytokine Production. QRT-PCR demonstrated that the mRNA levels of TNF-α, IL-6, and IL-8 were upregulated evidently in the IL-1β-stimulated group. However, in comparison with the IL-1β group, the mRNA levels were markedly decreased in the GLA-treated chondrocytes (Figures 4(a)–4(c)). Similarly, the contents of inflammatory factors were significantly induced by...
IL-1β, which were attenuated in the GLA-treated chondrocytes (Figures 4(d)–4(f)).

3.5. Effect of GLA on the Expression of MMPs. According to the results of qRT-PCR, chondrocytes in the IL-1β-stimulated group had increased mRNA levels of MMP-3 and MMP-13. While compared to the IL-1β-treated group, chondrocytes in the GLA-treated group had lower expressions of MMPs at mRNA level (Figures 5(a) and 5(b)). In addition, the results of ELISA assay indicated that GLA greatly inhibited the production of MMPs in chondrocytes (Figures 5(c) and 5(d)).

3.6. Effect of GLA on the Expression of ADAMTSs. Compared to the control group, the mRNA levels of ADAMTS-4 and ADAMTS-5 in the chondrocytes from the IL-1β-treated group were significantly increased, which were suppressed by GLA treatment (Figures 6(a) and 6(b)). In addition, we observed that IL-1β greatly increased the protein levels of ADAMTS-4 and ADAMTS-5, which were downregulated after the pretreatment with GLA (Figure 6(c)).

3.7. Effect of GLA on the Expression of Aggrecan and Collagen II. IL-1β could decrease the mRNA expression levels of aggrecan and collagen II. However, GLA upregulated the mRNA expression levels of aggrecan and collagen II in OA chondrocytes (Figures 7(a) and 7(b)). Similarly, the western blot assay revealed comparable results in aggrecan and collagen II protein expression levels (Figure 7(c)).

3.8. Effect of GLA on the NF-κB Pathway. The results from immunofluorescence indicated that IL-1β induced p65 nuclear accumulation, whereas the p65 accumulation was prevented by GLA (Figure 8(a)). The phosphorylation levels of p65 and IκBα were increased in the IL-1β-treated chondrocytes, while IκBα level was greatly decreased by IL-1β treatment. However, GLA prevented NF-κB activation in the IL-1β-treated chondrocytes (Figures 8(b) and 8(c)).

4. Discussion

The recent work in OA-associated field has implicated inflammatory chemokines in OA pathogenesis. Interleukins are a big family of cytokines that comprises 11 members that shared similar gene structure [17]. IL-1β is involved in the pathology of OA [7]. IL-1β binds to the type I IL-1RI [18]. It was reported that increased levels of IL-1RI are detected in isolated chondrocytes. It is evident that during inflammatory processes, increased IL-1β increases IL-1RI expression. The extracellular domain of IL-1RI causes IL-1 receptor accessory protein recruitment, which is considered a coreceptor for IL-1β signal transduction [7]. Next, the signal transduction causes the activation of MAPK pathways and eventually results in various transcription factors activation, such as NF-κB [7]. Collectively, IL-1β signaling is necessary for the development of OA and serves as a therapeutic target.
Here, we used IL-1β to induce an in vitro inflammatory OA model in chondrocytes, thereby exploring the anti-inflammatory effect of GLA exposed to IL-1β induction. IL-1β produces the production of proinflammatory cytokines, further induces iNOS expression, which results in NO accumulation [19]. Moreover, NO level is highly increased in OA chondrocytes as well as cartilage tissues [20]. NO inhibits the synthesis of proteoglycan and collagen and activates MMPs [21, 22]. Our results proved that GLA suppressed iNOS expression and NO release in chondrocytes. Like NO, PGE2, a predominant product of COX-2, is also increased during the progression of OA [19]. In human chondrocytes, the induction with IL-1β causes increased PGE2 release via regulating p38 MAPK pathway [23]. We also found that GLA suppressed the COX-2 expression and PGE2 release in IL-1β-induced chondrocytes.

In addition to acting as a key proinflammatory cytokine, IL-1β also contributes to the OA progression via mediating other events, such as inducing the expression of MMPs and ADAMTSs, which are cartilage-degrading enzymes [24–26]. IL-1β stimulates chondrocytes to release several types of MMPs, and these three proteases become a strategy to prevent OA [27, 28]. Moreover, the ADAMTS family of proteins, especially ADAMTS-4 and ADAMTS-5, is also

**Figure 6**: Modulation of ADAMTS-4 and ADAMTS-5 expression by GLA in human OA chondrocytes. Primary human OA chondrocytes were incubated with different concentrations of GLA (0, 5, 10, and 20 μM) for 2 h and then stimulated with IL-1β (10 ng/ml) for 24 h. (a and b) The mRNA levels of ADAMTS-4 and ADAMTS-5 were evaluated using qRT-PCR. (c) The protein levels of ADAMTS-4 and ADAMTS-5 were evaluated using western blot. *p < 0.05 versus the control group; #p < 0.05 versus the IL-1β group.
important in cartilage degradation [29]. We found that the elevated expression of MMPs and aggrecan and collagen II degradation were reversed by GLA in chondrocytes.

The NF-κB plays a crucial role in inflammation through modulating activation or repression of target gene expression [30]. Consequently, NF-κB is essential in various inflammatory diseases including OA [31]. NF-κB mediates critical inflammatory events by modulating chondrocytes, results in progressive extracellular matrix (ECM) damage [32]. The NF-κB signaling was found to be regulated by IL-1β in OA chondrocytes [33]. Thus, we evaluated the role of GLA in NF-κB pathway. NF-κB is commonly presented in an inactive form in the cytoplasm associated with the inhibitory κB proteins (IκB) [34]. The IκBα is an important mechanism for the activation and repression of NF-κB [35]. We found that GLA decreased the levels of p-p65 and suppressed the p65 accumulation in nucleus, which indicated that GLA prevented NF-κB pathway activation [36].

There existed several limitations in this study. A major limitation is that our results are based on the in vitro experiments. Future in vivo experiments are needed to verify the role of GLA in OA. Secondly, the exact molecular mechanisms by which GLA regulates NF-κB pathway need to be further explored in the future study.

In light of this, we concluded that GLA attenuated the inflammatory response and cartilage degradation in

![Figure](image-url)
chondrocytes via the regulation of NF-κB. Thus, GLA might become an effective therapeutic agent for OA.

Data Availability

The datasets used during the present study are available from the corresponding author upon reasonable request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] S. Glyn-Jones, A. J. Palmer, R. Agricola et al., “Osteoarthritis,” Lancet, vol. 386, no. 9991, pp. 376–387, 2015.

[2] D. Pereira, E. Ramos, and J. Branco, “Osteoarthritis,” Acta Médica Portuguesa, vol. 28, no. 1, pp. 99–106, 2015.

[3] C. R. Scanzello, “Chemokines and inflammation in osteoarthritis: insights from patients and animal models,” Journal of Orthopaedic Research, vol. 35, no. 4, pp. 735–739, 2017.

[4] S. Vila, “Inflammation in osteoarthritis,” Puerto Rico Health Sciences Journal, vol. 36, no. 3, pp. 123–129, 2017.

[5] J. Shen, Y. Abu-Amer, R. J. O’Keefe, and A. McAlinden, “Inflammation and epigenetic regulation in osteoarthritis,” Connective Tissue Research, vol. 58, no. 1, pp. 49–63, 2017.

[6] M. Kapoor, J. Martel-Pelletier, D. Lajeunesse, J. P. Pelletier, and H. Fahmi, “Role of proinflammatory cytokines in the pathophysiology of osteoarthritis,” Nature Reviews Rheumatology, vol. 7, no. 1, pp. 33–42, 2011.

[7] Z. Jenei-Lanzl, A. Meurer, and F. Zaucke, “Interleukin-1β signaling in osteoarthritis - chondrocytes in focus,” Cellular Signalling, vol. 53, pp. 212–223, 2019.
Disease Markers

[8] Z. Xiang, X. Wu, X. Liu, and Y. Jin, "Glaucocalyxin a: a review," *Natural Product Research*, vol. 28, no. 24, pp. 2221–2236, 2014.

[9] X. Jiang, Z. Zhang, C. Song et al., "Glaucocalyxin A reverses EMT and TGF-β1-induced EMT by inhibiting TGF-β1/Smad2/3 signaling pathway in osteosarcoma," *Chemico-Biological Interactions*, vol. 307, pp. 158–166, 2019.

[10] X. Liu, D. Xu, Y. Wang et al., "Glaucocalyxin a ameliorates myocardial ischemia-reperfusion injury in mice by suppression of microvascular thrombosis," *Medical Science Monitor*, vol. 22, pp. 3595–3604, 2016.

[11] W. Li, X. Tang, W. Yi et al., "Glaucocalyxin a inhibits platelet activation and thrombus formation preferentially via GPVI signaling pathway," *PLoS One*, vol. 8, no. 12, article e85120, 2013.

[12] M. Mao, T. Zhang, Z. Wang et al., "Glaucocalyxin A-induced oxidative stress inhibits the activation of STAT3 signaling pathway and suppresses osteosarcoma progression in vitro and in vivo," *Biochimica et Biophysica Acta - Molecular Basis of Disease*, vol. 1865, no. 6, pp. 1214–1225, 2019.

[13] X. Hou, G. Xu, Z. Wang et al., "Glaucocalyxin a alleviates LPS-mediated septic shock and inflammation via inhibiting NLRP3 inflammasome activation," *International Immunopharmacology*, vol. 81, article 106271, 2020.

[14] B. W. Kim, S. Koppula, S. S. Hong et al., "Regulation of microglia activity by gaucochlorin-X: attenuation of lipopolysaccharide-stimulated neuroinflammation through NF-κb and p38 MAPK signaling pathways," *PLoS One*, vol. 8, no. 2, article e55792, 2013.

[15] S. Zhu, J. Zhang, and Y. Lv, "Glaucocalyxin a inhibits hydrogen peroxide-induced oxidative stress and inflammatory response in coronary artery smooth muscle cells," *Clinical and Experimental Pharmacology & Physiology*, vol. 47, no. 5, pp. 765–770, 2020.

[16] M. Scotece, J. Conde, V. Abella et al., "Oleocanthal inhibits cathepsin B and p38 MAPK signaling pathways, *PLoS One*, vol. 8, no. 2, article e55792, 2013.

[17] T. Yoshimoto, N. Morishima, M. Okumura, Y. Chiba, M. Xu, and J. Mizuguchi, "Interleukins and cancer immunotherapy," *Immunotherapy*, vol. 1, no. 5, pp. 825–844, 2009.

[18] M. Bujak and N. G. Frangogiannis, "The role of IL-1 in the pathogenesis of heart disease," *Archivum Immunologiae et Therapiae Experimentalis (Warsz)*, vol. 57, no. 3, pp. 165–176, 2009.

[19] S. B. Abramson, "Osteoarthritis and nitric oxide," *Osteoarthritis and Cartilage*, vol. 16, Supplement 2, pp. S15–S20, 2008.

[20] S. B. Abramson, "Nitric oxide in inflammation and pain associated with osteoarthritis," *Arthritis Research & Therapy*, vol. 10, Supplement 2, p. S2, 2008.

[21] D. Taskiran, M. Stefanovicacriac, H. Georgescu, and C. Evans, "Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1," *Biochemical and Biophysical Research Communications*, vol. 200, no. 1, pp. 142–148, 1994.

[22] F. J. Blanco, R. L. Ochs, H. Schwarz, and M. Lotz, "Chondrocyte apoptosis induced by nitric oxide," *The American Journal of Pathology*, vol. 146, no. 1, pp. 75–85, 1995.

[23] A. M. Badger, A. K. Roshak, M. N. Cook et al., "Differential effects of SB 242235, a selective p38 mitogen-activated protein kinase inhibitor, on IL-1 treated bovine and human cartilage/